retatrutide creator Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application Retatrutide, an experimental weight-loss drug,

So these medications have a certain efficacy and effectiveness, and they produce a certain amount of weight loss in an individual, and then that weight loss stops, and that's completely normal

In clinical trials, diarrhea was reported as the third most common side effect in about 8% of people taking the medication

Noteworthy, renal ANG II concentration decreased without affecting plasma ANG II concentrations

Glutathione supplementation should never replace evidence-based lifestyle interventions, which remain the primary treatment for fatty liver disease

Med Sci

195,196 Future research should elucidate the roles of SIRT1 in the microbiotaimmunemetabolism cross-pathways and evaluate its potential therapeutic synergy with microbiota-targeted interventions, including probiotics and dietary fibers